Coinbase, eBay receive upgrades from leading Wall Street analyst

Top 5 Upgrades

Citizen JMP has upgraded eBay (EBAY) to outperform, setting a target price of $115. They believe that eBay’s new product initiatives will enhance the consumer experience in key areas, potentially leading to mid-single-digit growth in volume by 2026.

JP Morgan lifted Coinbase (COIN) from neutral to overweight, raising the price target from $342 to $404. They see Coinbase’s valuation as appealing, suggesting that its cryptocurrencies offer monetization opportunities and help mitigate risks for the company.

Morgan Stanley moved Tractor Supply (TSCO) from underweight to equal weight, increasing the price target from $50 to $60. They mentioned that the company is transitioning out of its investment cycle, with comparisons coming back to more normalized levels.

Kief Bruillette upgraded AppFolio (APPF) to outperform with a new price target of $311. This decision comes after a 31% decline in the stock since early August, with expectations for revenue growth to exceed 20% thanks to new AI products and resident services. There seems to be a belief that this potential growth has been underestimated, and their investor day in November could trigger interest.

UBS upgraded Alliant Energy (LNT) from neutral to buy, raising the price target from $74 to $79. They anticipate that increased workloads and capital spending, along with regulatory changes, will boost the stock price.

Top 5 Downgrades

Barclays has downgraded Molina Healthcare (MOH) from equal weight to underweight, reducing the target price from $185 to $144. They think the company’s earnings forecast for 2026 is overly optimistic, especially regarding Medicaid medical loss rates.

Wells Fargo downgraded Integer (ITGR) from overweight to equal weight, adjusting the price target from $132 to $80. Their revised fourth-quarter guidance and 2026 outlook fell well below market expectations. Other firms like BofA and Benchmark have also downgraded it to a neutral stance.

Jefferies has changed Inspire Medical (INSP) from buy to hold, lowering the price target from $160 to $85. Concerns over headwinds from weight-loss drugs, competitors gaining market share, and modest volume growth expectations have contributed to this decision.

Wainwright downgraded Arcturus Therapeutics (ARCT) from buy to neutral, slashing the price target from $60 to $12. Conversations with key opinion leaders indicated that their cystic fibrosis program may not be suitable for late-stage clinical trials.

Sidoti adjusted Plexus (PLXS) from buy to neutral with a price target of $150. While they view the fourth quarter as solid, the company has lowered its forecasts for FY26 and FY27, taking a cautious stance on the macro environment and feedback from management.